On October 17, the National Pharmaceutical Pricing Authority (NPPA) notified a second round of trade margin rationalisation covering 137 non-scheduled anti-cancer drugs. The revised prices, effective November 9, cover 643 brand-strength-pack entries and include 34 drugs that were part of the original 2019 exercise. India Today reported the notification after a Supreme Court nudge for the government to examine ways to rein in cancer treatment costs, including supply-chain margins.
The arithmetic behind the new list is stark. An analysis by the Third World Network finds nearly three-fourths of listed entries will see price reductions, with an average cut of about 38 per cent. Some 124 entries will become more than 70 per cent cheaper. The steepest fall is Samtepa, a 100 mg thiotepa injection, whose price drops from Rs 80,072 to about Rs 7,150 per vial.
The scale of those cuts reveals how much room prices and margins had to rise after the first intervention. In 2019, the NPPA capped trade margins on 42 non-scheduled cancer drugs at 30 per cent, according to a Times of India report that now records markups of 700 per cent on some products. The distance between a 30 per cent cap and a 700 per cent markup is the distance between policy intention and pharmacy receipt.
The second round follows a push from the Supreme Court for the government to examine ways to rein in the cost of cancer treatment, including the margins charged across the drug supply chain. That judicial attention came after a decade in which India's cancer burden has grown impossible to ignore. The country recorded around 1.5 million new cancer cases in 2022. An Indian Council of Medical Research study published in The Lancet Regional Health – Southeast Asia projects annual cases approaching 2.7 million by 2050, with deaths rising from around 990,000 to 1.83 million.
Why a 30 per cent cap became a 700 per cent markup
The central failure is not in the 2019 notification but in the gap between a maximum trade margin and the actual price charged at a hospital pharmacy or retail counter. When the regulator caps the margin between the manufacturer's ceiling price and the retail price, it does not necessarily observe the price at which the medicine changes hands further down the chain. Distributors, stockists, and hospital in-house pharmacies can re-inflate the final markup through handling fees, procurement charges, or bundled service costs. The NPPA's statistical exercise counts maximum permissible margins, while the patient's bill counts something else.
That structural gap explains why a second round of rationalisation became necessary less than a decade after the first. The 2019 intervention was designed to cut retail prices significantly; the India Today report of the new cuts, with an average reduction of 38 per cent, shows how much of that intended gain had evaporated. If the cap had held at the point of sale, a 100 mg thiotepa injection would never have reached Rs 80,072 to begin with after being pulled down in the first round.
What this means for the Indian patient
Cancer treatment in India remains a heavily out-of-pocket affair for most households. The source report notes that treatment often involves prolonged chemotherapy, targeted therapies and expensive immunotherapy, and the price of medicines can determine whether patients complete a regimen or abandon it. When a single vial drops from Rs 80,072 to Rs 7,150, the arithmetic of survival changes. But when margins rebound in the intervening years, thousands of families absorb the difference without any regulatory correction until a fresh notification arrives.
The recurrence of the problem suggests that trade margin rationalisation, as currently practiced, is a periodic reset rather than a durable price ceiling. That is not an argument against the NPPA's authority; it is an argument for moving from notified maximums to verifiable transaction-level monitoring. The regulator can publish a lower maximum retail price, but it cannot tell from that gazette notification whether a hospital's pharmacy applied an additional service charge, whether a distributor billed an informal handling fee, or whether a stockist simply held inventory until the old higher-priced stock cleared.
The case for extending margin discipline
ThePrint's editorial page has argued that drug price caps cannot stop at cancer medicines and that India needs to regulate pharma margins across the board. ThePrint frames the issue as one of regulatory architecture: if the state sets a margin for one therapeutic category, the same logic applies to other high-cost treatments. The cancer rebound gives that argument empirical weight. A margin cap that works only until the next price notification cycle is not a cap at all; it is a scheduled discount that the supply chain anticipates.
India's generic pharmaceutical industry is globally competitive, and domestic manufacturers have little interest in undermining their own volume business. The more significant friction lies with distribution intermediaries and hospital procurement desks, which benefit from opaque pricing. Any durable solution must include electronic tracking of actual transaction prices and linkage of government procurement and insurance reimbursement to verified point-of-sale data. Without that, the NPPA's notifications will remain a series of resets rather than a structural correction.
The institutional lesson of 2019
The NPPA's 2019 exercise, like the current one, relied on a legal provision that allows the regulator to cap margins on non-scheduled drugs when public health requires it. That authority is sound. What the intervening seven years revealed is that a margin cap imposed at the manufacturer-to-retailer segment does not automatically discipline the hospital-to-patient segment. A patient admitted for chemotherapy rarely buys the infusion from a standalone pharmacy; the hospital's in-house dispensary prices the drug as part of the treatment episode, often without a separate itemised margin that the regulator can inspect.
This does not mean the NPPA's action was futile. It means the regulator's next step must be to require electronic invoicing of every cancer medicine transaction, from wholesaler to hospital to bedside, and to make that data inspectable. India's digital public infrastructure has already demonstrated that transaction-level visibility is feasible in other sectors. Applying the same logic to pharmaceutical distribution would transform margin rationalisation from a periodic notification into a continuous price discipline.
The 2019 cap was not a failure of intent; it was a demonstration that a price notification is not the same as a price paid. The November 9 revision will bring immediate relief to households facing a new diagnosis, and that relief is real. But the question Indian readers should carry from this episode is whether the regulator will now build the monitoring infrastructure to ensure a 38 per cent average cut does not simply become the starting point for the next round of markups. Cancer has no political constituency and no seasonal respite. The only durable response is a pricing system that closes the gap between the gazette and the cash register.
